Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win

Why Is Kailera Therapeutics Stock Falling Tuesday?

Kailera's GLP-1 drug meets main goal of late-stage trials

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Biotech ETF Index Surges 10% After Rebalance

3 Under-the-Radar Stocks to Buy and Hold for a Decade

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

Is Kailera Therapeutics a Buy After Its Sizzling IPO?

This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst

Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

A Kailera Therapeutics (KLRA) Insider Scooped up an Additional 500,000 Shares for $8.0 Million

First Look: Meta cuts, Intel beats, oil jumps, Apple shift

Rtw Investments, Lp Acquires 500,000 Shares of Kailera Therapeutics (NASDAQ:KLRA) Stock

Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy

First Look: Tesla beats, WBD vote, oil near $100, AI moves

Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race

Kailera Therapeutics Announces Pricing of Initial Public Offering